reference/14544493

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/14544493

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Clinical Trial, Phase I\|Journal Article
endingPage	337
issn	0344-5704 1432-0843
issueIdentifier	4
pageRange	333-337
publicationName	Cancer Chemotherapy and Pharmacology
startingPage	333
bibliographicCitation	Fyfe D, Price C, Langley RE, Pagonis C, Houghton J, Osborne L, Woll PJ, Gardner C, Baguley BC, Carmichael J; Cancer Research Campaing Phase I/II Trials Committee. A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule. Cancer Chemother Pharmacol. 2001 Apr;47(4):333–7. doi: 10.1007/s002800000216. PMID: 11345650.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1ad5a83e96cd0f6c3f999d04fd8657fc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_560b97f1ea422dad7d37e81921338467 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a5b38d719203e6446aeb0c3860a2657c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_702572ed7d2be6e3ef61ae9cd17c3353 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4632d640e57aef4e0be70f2591f5a5b4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7f066efe36302415e45eaafcf0cb777f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7b3679ea385f56dfb4267a24675f9bdd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_59fbac10bbce75a531fc9a443929826e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_988f5b3d80a4ab240f158bc780e5bbb1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_eb9fbdee58df7999123fc8b0f2d3dfb9
date	2001-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1007/s002800000216 https://pubmed.ncbi.nlm.nih.gov/11345650
isPartOf	https://portal.issn.org/resource/ISSN/0344-5704 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2664 https://portal.issn.org/resource/ISSN/1432-0843
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/ https://scigraph.springernature.com/
title	A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule
discusses	http://id.nlm.nih.gov/mesh/M0545767 http://id.nlm.nih.gov/mesh/M0538155 http://id.nlm.nih.gov/mesh/M0007520 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0001039
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D004791Q000627 http://id.nlm.nih.gov/mesh/D000677Q000031 http://id.nlm.nih.gov/mesh/D059005 http://id.nlm.nih.gov/mesh/D000677Q000627 http://id.nlm.nih.gov/mesh/D009369Q000188 http://id.nlm.nih.gov/mesh/D000970Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D004791Q000009 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D000677Q000009 http://id.nlm.nih.gov/mesh/D007262 http://id.nlm.nih.gov/mesh/D004791Q000008 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D001855Q000139 http://id.nlm.nih.gov/mesh/D000970Q000009 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000970Q000008 http://id.nlm.nih.gov/mesh/D019540 http://id.nlm.nih.gov/mesh/D006207 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000677Q000008 http://id.nlm.nih.gov/mesh/D004305
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID157348 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID107924 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8872 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9614 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7905 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7019 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7078

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129696811 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129669639

Total number of triples: 72.